AU2020413313B2 - Prophylactic and/or therapeutic agent for chronic prostatitis/chronic pelvic pain syndrome - Google Patents

Prophylactic and/or therapeutic agent for chronic prostatitis/chronic pelvic pain syndrome

Info

Publication number
AU2020413313B2
AU2020413313B2 AU2020413313A AU2020413313A AU2020413313B2 AU 2020413313 B2 AU2020413313 B2 AU 2020413313B2 AU 2020413313 A AU2020413313 A AU 2020413313A AU 2020413313 A AU2020413313 A AU 2020413313A AU 2020413313 B2 AU2020413313 B2 AU 2020413313B2
Authority
AU
Australia
Prior art keywords
amino
carbonyl
carboxamide
benzimidazole
chloro
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2020413313A
Other languages
English (en)
Other versions
AU2020413313A1 (en
Inventor
Maki Kurita
Ken Okamoto
Hiroshi Yamaguchi
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Nippon Shinyaku Co Ltd
Original Assignee
Nippon Shinyaku Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nippon Shinyaku Co Ltd filed Critical Nippon Shinyaku Co Ltd
Publication of AU2020413313A1 publication Critical patent/AU2020413313A1/en
Application granted granted Critical
Publication of AU2020413313B2 publication Critical patent/AU2020413313B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/416—1,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/423—Oxazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Urology & Nephrology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
AU2020413313A 2019-12-25 2020-12-24 Prophylactic and/or therapeutic agent for chronic prostatitis/chronic pelvic pain syndrome Active AU2020413313B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2019233865 2019-12-25
JP2019-233865 2019-12-25
PCT/JP2020/048479 WO2021132472A1 (ja) 2019-12-25 2020-12-24 慢性前立腺炎／慢性骨盤痛症候群の予防及び／又は治療剤

Publications (2)

Publication Number Publication Date
AU2020413313A1 AU2020413313A1 (en) 2022-07-14
AU2020413313B2 true AU2020413313B2 (en) 2025-11-27

Family

ID=76575232

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2020413313A Active AU2020413313B2 (en) 2019-12-25 2020-12-24 Prophylactic and/or therapeutic agent for chronic prostatitis/chronic pelvic pain syndrome

Country Status (16)

Country Link
US (1) US12599589B2 (https=)
EP (1) EP4082573A4 (https=)
JP (3) JP7499789B2 (https=)
KR (1) KR20220120646A (https=)
CN (2) CN119303087A (https=)
AU (1) AU2020413313B2 (https=)
BR (1) BR112022012485A2 (https=)
CA (1) CA3165891A1 (https=)
CO (1) CO2022010343A2 (https=)
EC (1) ECSP22058286A (https=)
IL (1) IL294191A (https=)
MX (1) MX2022007936A (https=)
PE (1) PE20230164A1 (https=)
PH (1) PH12022551578A1 (https=)
UA (1) UA130283C2 (https=)
WO (1) WO2021132472A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116082247B (zh) * 2023-01-19 2025-08-01 浙江工业大学 一种苯并咪唑类衍生物及其应用
CN121401398A (zh) * 2025-12-29 2026-01-27 汕头市中心医院 一种实验性自身免疫性前列腺炎大鼠模型的构建方法

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011048004A1 (en) * 2009-10-23 2011-04-28 Boehringer Ingelheim International Gmbh Inhibitors of the microsomal prostaglandin e2 synthase-1
EP2746265A1 (en) * 2011-08-18 2014-06-25 Nippon Shinyaku Co., Ltd. Heterocyclic derivative and pharmaceutical drug
EP3372589A1 (en) * 2015-10-29 2018-09-12 ASKA Pharmaceutical Co., Ltd. Pyrimidine derivative

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UY32470A (es) 2009-03-05 2010-10-29 Boehringer Ingelheim Int Derivados de 2-{2-cloro-5-[(sustituido) metil]fenilamino} -1-metil]fenilamino}-1-metilbencimidazol-5-carboxamidas-n-(sustituidas) y sus sales fisiológicamente aceptables, composiciones conteniéndolos y aplicaciones
WO2011023812A1 (en) 2009-08-27 2011-03-03 Novasaid Ab Microsomal prostaglandin e synthase-1 (mpges1) inhibitors
TW201206440A (en) * 2010-04-28 2012-02-16 Astellas Pharma Inc Prophylactic or therapeutic agent for diseases associated with pains in urinary organs
US8759537B2 (en) 2010-08-20 2014-06-24 Boehringer Ingelheim International Gmbh 3H-imidazo [4, 5-C] pyridine-6-carboxamides as anti-inflammatory agents
US8586604B2 (en) 2010-08-20 2013-11-19 Boehringer Ingelheim International Gmbh Inhibitors of the microsomal prostaglandin E2 synthase-1
UY33779A (es) 2010-12-10 2012-07-31 Boehringer Ingelheim Int ?2-(fenilamino)-1H-bencimidazol-5-carboxamidas novedosas?
AR086254A1 (es) 2011-05-26 2013-11-27 Lilly Co Eli Derivados de imidazol utiles para el tratamiento de artritis
CN104039956A (zh) * 2011-11-04 2014-09-10 葛兰素史密斯克莱知识产权（第2号）有限公司 治疗方法

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011048004A1 (en) * 2009-10-23 2011-04-28 Boehringer Ingelheim International Gmbh Inhibitors of the microsomal prostaglandin e2 synthase-1
EP2746265A1 (en) * 2011-08-18 2014-06-25 Nippon Shinyaku Co., Ltd. Heterocyclic derivative and pharmaceutical drug
EP3372589A1 (en) * 2015-10-29 2018-09-12 ASKA Pharmaceutical Co., Ltd. Pyrimidine derivative

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
NAUSCH B ET AL: "262 Canephron N reduces pain in experimental cystitis and prostatitis putatively by inhibition of PGE2 production", EUROPEAN UROLOGY SUPPLEMENTS, vol. 15, no. 3, 1 January 2016, page 1, DOI: 10.1016/S1569-9056(16)60264-6. *

Also Published As

Publication number Publication date
ECSP22058286A (es) 2022-09-30
JP2024103724A (ja) 2024-08-01
JP2026015542A (ja) 2026-01-29
MX2022007936A (es) 2022-10-27
PE20230164A1 (es) 2023-02-01
CA3165891A1 (en) 2021-07-01
BR112022012485A2 (pt) 2022-09-06
EP4082573A4 (en) 2024-01-10
JPWO2021132472A1 (https=) 2021-07-01
NZ789736A (en) 2025-10-31
CO2022010343A2 (es) 2022-10-31
JP7779953B2 (ja) 2025-12-03
US12599589B2 (en) 2026-04-14
US20230094705A1 (en) 2023-03-30
CN114867495A (zh) 2022-08-05
AU2020413313A1 (en) 2022-07-14
JP7499789B2 (ja) 2024-06-14
PH12022551578A1 (en) 2023-11-29
WO2021132472A1 (ja) 2021-07-01
EP4082573A1 (en) 2022-11-02
CN119303087A (zh) 2025-01-14
KR20220120646A (ko) 2022-08-30
UA130283C2 (uk) 2026-01-07
CN114867495B (zh) 2024-10-18
IL294191A (en) 2022-08-01

Similar Documents

Publication Publication Date Title
USRE49556E1 (en) Compounds and compositions as protein kinase inhibitors
CN113646307B (zh) 具有蛋白激酶抑制活性的吡啶并[3,4-d]嘧啶-8-酮衍生物及其药物组合物
CN104936951B (zh) 作为激酶抑制剂的苯并咪唑衍生物
EP2498607B1 (en) Kinase inhibitors
JP5451602B2 (ja) キナーゼ阻害薬としての５−ヘテロアリール置換インダゾール類
US10160746B2 (en) 1H-indazole-3-carboxamide compounds as glycogen synthase kinase 3 beta inhibitors
JP7779953B2 (ja) 慢性前立腺炎／慢性骨盤痛症候群の予防及び／又は治療剤
HUE026671T2 (en) Heterocyclic derivatives as microsomal prostaglandin E synthetase inhibitors (mPGEs)
RU2836236C1 (ru) Профилактическое и/или терапевтическое средство против хронического простатита/синдрома хронической тазовой боли
HK40081072A (en) Prophylactic and/or therapeutic agent for chronic prostatitis/chronic pelvic pain syndrome
US20230036867A1 (en) N-(3-(5-(pyrimidin-4-yl)thiazol-4-yl)phenyl)sulfonamide compounds and their uses as braf inhibitors
RU2780168C1 (ru) Новое производное пиридо [3,4-d] пиримидин-8-она, обладающее ингибирующей протеинкиназы активностью, и фармацевтическая композиция для предупреждения, облегчения или лечения рака, содержащее указанное выше
WO2025133653A1 (en) Imidazole derivatives and use thereof as antifibrotic agents
AU2010319382B2 (en) Kinase inhibitors
US20240285621A1 (en) Pyrazolyl-pyrimidine derivatives as kinase inhibitors
HK1167390B (en) Compounds and compositions as protein kinase inhibitors
HK1191936A (en) Compounds and compositions as protein kinase inhibitors

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)